Furthermore, as examined by Skilling et al. in their study on primary ovarian tumors, the prevalence of TP53 gene mutations or overexpression is higher in serous primary ovarian cancers, with rates of 58% and 59%, respectively [17]. This evidence concerns the gene TP53 and ovarian neoplasm.